Drug intelligence / Profile preview

Indomirol

Development stage: Unknown
Lead developer: NutriMed
Modality: Small Molecules
Administration: Oral

Overview

Indomirol is a multi-component nutraceutical developed by NutriMed Group, designed to support the functional state of the female reproductive system. It contains indole-3-carbinol, diindolylmethane (DIM), and resveratrol. These components work synergistically to modulate estrogen metabolism, specifically favoring the production of 2-hydroxyestrone over 16-alpha-hydroxyestrone, thereby reducing the risk of hormone-dependent proliferative diseases such as endometriosis, uterine fibroids, and mastopathy. Additionally, it exhibits antioxidant properties and may inhibit the expression of oncoproteins associated with Human Papillomavirus (HPV).

Brand names: Indomirol

Targets

COX

Beyond the preview

Go deeper on Indomirol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Indomirol.

Explore the full profile